Scarica l'app Stockscreener
2.21
0.00%
0.00
Precedente Chiudi:
$2.21
Aprire:
$2.185
Volume 24 ore:
10,819
Relative Volume:
0.05
Capitalizzazione di mercato:
$6.97M
Reddito:
$960.60K
Utile/perdita netta:
$-7.10M
Rapporto P/E:
-0.2923
EPS:
-7.56
Flusso di cassa netto:
$-8.00M
1 W Prestazione:
-5.15%
1M Prestazione:
-4.33%
6M Prestazione:
-54.62%
1 anno Prestazione:
-74.42%
Intervallo 1D:
$2.17
$2.24
Intervallo di 1 settimana:
$2.10
$2.31
Portata 52W:
$1.8301
$14.92
Soligenix Inc Stock (SNGX) Company Profile
Nome
Soligenix Inc
Settore
Industria
Telefono
609-538-8200
Indirizzo
29 EMMONS DRIVE, PRINCETON
Confronta SNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
2.21 | 6.97M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-28 | Downgrade | Dawson James | Buy → Neutral |
| 2018-01-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Reiterato | Maxim Group | Buy |
| 2017-07-17 | Iniziato | H.C. Wainwright | Buy |
Soligenix Inc Borsa (SNGX) Ultime notizie
Zacks Small Cap Decreases Earnings Estimates for Soligenix - Defense World
Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap - Defense World
SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19… - Yahoo Finance
CiVax booster shows broad COVID-19 variant protection By Investing.com - Investing.com South Africa
IBN Initiates Coverage of Soligenix Inc. - GlobeNewswire
First National Financial Corporation to Host First Quarter Earnings Call on April 30, 2025 - The Globe and Mail
CiVax booster shows broad COVID-19 variant protection - Investing.com
Revolutionary Heat-Stable COVID Booster Outperforms mRNA Vaccines Against Variants - Stock Titan
Soligenix Inc. (SNGX) reports earnings - Quartz
SOLIGENIX, INC. SEC 10-K Report - TradingView
Soligenix Trumps Year-End Financials - Baystreet.ca
Soligenix reports progress and 2024 financials By Investing.com - Investing.com Australia
Soligenix reports progress and 2024 financials - Investing.com India
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - Quantisnow
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Soligenix Financial Results Reveal Widening Losses While Clinical Pipeline Expands - StockTitan
Why Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix Inc expected to post a loss of 95 cents a shareEarnings Preview - TradingView
Soligenix (SNGX) Projected to Post Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’ - Financial Content
Soligenix (SNGX) Projected to Post Earnings on Thursday - Armenian Reporter
AllPennyStocks.com News: A Steady Stream of News and Developments Pushes Soligenix Near 52 Week High - ACCESS Newswire
Soligenix, Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest - Defense World
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - Yahoo Finance
Soligenix (SNGX) Projected to Post Quarterly Earnings on Thursday - Defense World
BiomednewsbreaksSoligenix Inc. (SNGX) To Present Hybrytetm And SGX302 Data At Dermatology Conferences - MENAFN.COM
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases - The Globe and Mail
Soligenix Advances Innovative Treatments for Rare Diseases - citybuzz -
TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight - GlobeNewswire Inc.
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026 - The Globe and Mail
Silicon Valley - Financial Content
SoundHound AI Stock at a Crossroads—Is a Bottom in Sight? - The Globe and Mail
Soligenix settles debt with Pontifax lenders - MSN
Soligenix, Inc. Repays and Terminates Loan Agreement with Pontifax Medison FinanceOn February 5, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced in an SEC Filing the full repayment and termination of all outstanding obligations under the Loan and Se - Defense World
Soligenix Repays Loan, Boosting Financial Flexibility - TipRanks
Soligenix on Way to Bio Conference in NYC - Baystreet.ca
Rare Disease Pioneer Soligenix Takes Center Stage at Major Biotech Investor Summit - StockTitan
Symbol Lookup - GuruFocus.com
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV - ACCESS Newswire
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Soligenix (NASDAQ:SNGX) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head to Head Contrast - Defense World
Soligenix (SNGX) Stock Price, News & Analysis - MarketBeat
Soligenix (NASDAQ: $SNGX) Unveils Two-Pronged Approach To Tackle Rare Diseases & Unmet Medical Needs - MSN
Soligenix to Present at Upcoming Investor Conferences - PR Newswire
Soligenix to Present at Two Major Investor Conferences in January 2024 - Stock Titan
Soligenix Inc Azioni (SNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):